EORTC – European Organisation for Research and Treatment of Cancer shared a post on LinkedIn:
“ESMO25 in Berlin has come to a close, and EORTC is proud to have contributed to the dialogue on advancing cancer research with a strong focus on patient needs and long-term outcomes.
From exploring what happens when patients stop treatment during trials, to improving how we measure quality of life, our teams presented new findings and launched promising new studies that reflect our mission: independent, innovative, and patient-centred research.
We’re grateful to all collaborators, patients, and partners who make this work possible.
More posts featuring ESMO25.